Eternity Healthcare has announced its intention to build a cell storage, transformation and application facility in Tongren, Guizhou Province, China. This 50,000-square foot facility will utilize the proprietary biotechnology developed by Shenzhen Zoken Biotechnology Co. LTD. Eternity is in preliminary negotiations regarding the specific terms of the license, whereby the Company will acquire the exclusive right to use Shenzhen Zoken Biotechnology’s technology for the harvesting, storage, transformation and application of stem cells throughout Guizhou Province. The Company will establish a facility in Tongren for the treatment of clients interested in the benefits of stem cell storage and applications, which will have a fully equipped stem cell laboratory, immune cell research room, and a genetics and gene research laboratory. It is estimated that construction of the facility, including acquisition of the equipment, and initial working capital, will require approximately $20 million. It is anticipated that the funds will be provided by affiliates of one of the Company’s shareholders, pursuant to a long-term loan. Once completed, the facility will provide its clients with treatments and services, similar to those provided by hospitals which rely upon Shenzhen Zoken Biotechnology to service their clients. Unlike those hospitals, which ship their patients’ stem cells to Shenzhen Zoken Biotechnology for storage and transformation, all work will be done on site at Eternity’s facility. The organizational structure should be completed by the end of November and the facility in Tongren will be operational by April 2018. As the terms of all of the relevant documents have yet to be negotiated, there can be no assurance that the Company will be able to establish the anticipated facility or that the relevant economic terms will be advantageous to its shareholders.